HUMAN GENOME, GSK TO DEVELOP NEW CANCER DRUG
Biopharmaceutical company Human Genome Sciences announced that GlaxoSmithKline
(GSK) has exercised its option to help develop and commercialize a cancer treatment.
The option involves HGS-ETR1, a human monoclonal antibody that binds to certain
cancer cells and induces cell death. In a 1996 agreement, GSK was given the
option to help the company develop and promote the treatment for 50 percent
of the cost and 50 percent of the profit.
Under the agreement, GSK will assist in late-stage and postmarket clinical trials
for the treatment. HGS-ETR1 is currently in mid-stage clinical trial for patients
with advanced non-small cell lung cancer, the most common form of lung cancer;
advanced non-Hodgkin's lymphoma, or cancer of the organs that make up the immune
system; and advanced colorectal cancer.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May